CPC A61K 31/496 (2013.01) [A61K 9/0019 (2013.01); A61K 9/10 (2013.01); A61K 47/26 (2013.01); A61K 47/38 (2013.01); A61P 25/18 (2018.01)] | 4 Claims |
1. An aripiprazole injectable suspension formulation having prolonged shelf life, comprising aripiprazole in an amount of 200 mg/mL;
sodium carboxymethyl cellulose in an amount selected from 4 mg/mL or 8 mg/mL;
mannitol in an amount of 40 mg/mL;
polyoxyethylene (20) sorbitan monooleate in an amount selected from 4 mg/mL, 8 mg/mL or 24 mg/mL; and
sodium dihydrogen phosphate in an amount of 0.6 mg/mL.
|